drugset / Trial / NCT07206537

The Role of Vitamin K2 in Preventing Glucocorticoid-Induced Bone Loss in Children With Nephrotic Syndrome

NCT07206537

Recruiting 60 enrolled Ain Shams University
Non-randomizedParallel-groupDouble-blindPrevention

Summary

Long-term glucocorticoids therapy is associated with various complications, including decreased bone strength (Glucocorticoid-induced osteoporosis) and an increased risk of fracture. Vitamin K2 has been recently deemed appreciable as a topic of research as it plays a pivotal role in maintenance of the bone strength, and it has been proved to have a positive impact on the bone metabolism. This study examines the impact of oral vitamin K2 supplementation on bone metabolism in pediatric patients with nephrotic syndrome on long-term steroid therapy, offering valuable therapeutic insights

Timeline

Start
2025-04-01
Primary completion
2026-04-30
Completion
2026-04-30

Drugs

EvaluationDrugModalityDoseRoute
Comparator Vitamin K2 Unknown Oral

Indications

No indication recorded.